Molecule of the month

Current Topics in Medicinal Chemistry

Volumn 8, Issue 14, 2008, Pages 1310-

  Felts, Andrew S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LAROPIPRANT; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SIMVASTATIN; TREDAPTIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; REVIEW; SIDE EFFECT;

EID: 52949093521     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608785849003     Document Type: Review

References (5)

1. The World Health Report 2004. Changing History. World Health Organization. 2004 Geneva, Switzerland.
2. Capuzzi, D.M.; Morgan, J.M.; Brusco, O.A. Jr.; Intenzo, C.M. Niacin doging: relationship to benefits and adverse effects. Curr. Atheroscler. Rep. 2000, 2, 64-71.
3. Cheng, K. et al. Antagonism of the prostaglandin D2 receptor one suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl. Acad Sci. USA 2006, 103, 6682-6687.
4. 2 receptor subtype 1. Clin. Pharmacol. Ther. 2007, 81, 6, 849-857.
5. Merck Sharp and Dohme. Press release. July 11, 2008. www.businesswire.com.